MedTrace Logo

Bupropion SR for Treating Smokeless Tobacco Use

NCT00414180 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2011-03-14

No results posted yet for this study

Summary

To determine the efficacy and safety of bupropion SR for quitting tobacco in smokeless tobacco users.

Conditions

  • Smokeless Tobacco

Interventions

DRUG

Bupropion SR

Sponsors & Collaborators

  • West Virginia University

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Lowell C. Dale, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00414180 on ClinicalTrials.gov